Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTMoby IntelligenceFri, August 7, 2026 at 11:12 PM GMT+2 3 min readTreace Medical Concepts, Inc. Q2 2026 Earnings Call Summary - MobyStrategic Performance DriversOur analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.The sequential improvement in revenue growth rate was driven by high single-digit case volume acceleration and increased surgeon adoption of the comprehensive bunion portfolio.Management attributed the year-over-year revenue decline to lower procedure kit sales to stocking distributors and a continued mix shift toward lower-priced minimally invasive products.The company is successfully expanding its addressable market by capturing the 75% of bunion procedures previously unaddressed by its core Lapiplasty system.Approximately 40% of the existing surgeon base has utilized at least one of the three new bunion systems launched in late 2025, up from 35% in the prior quarter.A 'pull-through' effect is emerging, where 30% of new surgeons who first adopted the newer bunion systems have subsequently utilized Lapiplasty technology.Strategic expansion into mid-foot and hind-foot procedures via the SuperBite system is enabling the sales force to capture a greater share of surgeon wallet across the entire foot.Profitability improved through organizational efficiencies and restructuring, resulting in reduced cash usage and better adjusted EBITDA leverage despite a lower revenue base.Outlook and Strategic InitiativesFull-year 2026 revenue guidance was raised to $204 million to $212 million, assuming a return to positive growth in the seasonally strongest fourth quarter.The fourth quarter recovery is predicated on accelerating case volumes and the annualization of the ASP mix shift dynamics from 2025 product launches.Management expects a limited commercial launch of the next-generation Lapiplasty Lightning platform in the fourth quarter to simplify surgical workflows and enhance accuracy.The company anticipates a 50% reduction in cash usage for the full year 2026, supported by continued operational discipline and restructuring benefits.Strategic focus remains on the full commercialization of the SuperBite system and the introduction of the CartiBlaster joint preparation rasps to strengthen the mid- and hind-foot portfolio.Operational Context and Risk FactorsRestructuring charges were taken during the quarter as the company continues to seek organizational efficiencies and improved bottom-line leverage.The company identified a $300 million incremental U.S. addressable market opportunity through its new mid-foot and hind-foot product combinations.Management noted that while the summer season is typically softer for bunion procedures, they have not seen a material impact from macro factors like ACA subsidy expirations.Direct sales channels now account for approximately 80% of total revenue, providing a focused platform for new technology launches.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info